Streetbeat News

Price Targets

ZM

Rosenblatt analyst Catharine Trebnick has reiterated a Neutral rating on Zoom Video Communications (NASDAQ:ZM) and maintained a $75 price target on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 1:47 pm

GETY

Wedbush analyst Michael Pachter has reiterated an Outperform rating on Getty Images Holdings (NYSE:GETY) and maintained a price target of $7.7.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 1:45 pm

BJRI

Wedbush analyst Nick Setyan has reiterated an Outperform rating on BJ's Restaurants (NASDAQ:BJRI) and maintained a price target of $33.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 1:40 pm

ALPN

Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Alpine Immune Sciences (NASDAQ:ALPN) and maintained a $26 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 1:38 pm

AFRM

Wedbush analyst David Chiaverini has reiterated an Underperform rating on Affirm Holdings (NASDAQ:AFRM) and maintained a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 1:36 pm

AFMD

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on Affimed (NASDAQ:AFMD) and maintained a $5 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 1:30 pm

ABSI

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on Absci (NASDAQ:ABSI) and maintained a price target of $4.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 1:28 pm

IPHA

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on Innate Pharma (NASDAQ:IPHA) and maintained a price target of $11.5.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 1:27 pm

RWLK

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on ReWalk Robotics (NASDAQ:RWLK) and maintained a price target of $3.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 1:24 pm

PRAX

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Praxis Precision Medicine (NASDAQ:PRAX) and maintained a $7 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 1:21 pm